参考文献/References:
[1] HAMILTON S P.The promise of psychiatric pharmacogenomics[J].Biol Psychiatry,2015,77(1):29-35.
[2] CRETTOL S,PETROVIC N,MURRAY M.Pharmacogenetics of phase I and phase IIdrug metabolism[J].Curr Pharm Des,2010,16(2):204-219.
[3] TING L S,BENOIT-BIANCAMANO M O,BER-NARD O,et al.Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients:an exploratory study[J].Pharmacotherapy,2010,30(11):1097-1108.
[4] MIKSYS S,TYNDALE RF.Cytochrome P450-mediated drug metabolism in the brain[J].J Psychiatry Neuro Sci,2013,38(3):152-163.
[5] 简斌,张涛,肖俊会,等.云南汉族人群CYP2C19基因多态性分析[J].昆明医科大学学报,2015,36(11):17-19. JIAN Bin,ZHANG Tao,XIAO Junhui,et al.Genetic polymorphism analysis of CYP2C19 in Yunnan Han population[J].Journal of Kunming Medical University,2015,36(11):17-19.
[6] 秦延海,古丽扎尔·买买提明,帕丽达·阿不来提.维吾尔族、哈萨克族、汉族人群CYP2C19基因多态性分析[J].重庆医学,2015,44(33):4632-4634. QIN Yanhai,GULIZHAER·Mainaitiming,PALIDA·Abulatib.Anlysis of genetic polymorphism of cytochrome CYP2C19 in Chinese Uighur,Kazak and Han populations[J].Chongqing Medicine,2015,44(33):4632-4634.
[7] 葛高顺,倪二茹,方宜臻,等.厦门地区心血管疾病患者外周血单个核细胞CYP2C19基因型与表型的分布研究[J].现代检验医学杂志,2018,33(4):8-11,15. GE Gaoshun,NI Erru,FANG Yizhen,et al.Study on the distribution of CYP2C19 genotypes and phenotypes mononuclear cells of peripheral blood from patients with cardiovascular diseases in Xiamen area[J].J Mod Lab Med,2018,33(4):8-11,15.
[8] 徐鹏,胡国艳,邱萍英,等.华南地区汉族精神分裂症患者CYP2C19基因多态性及代谢表型分析[J].深圳中西医结合杂志,2017,27(12):4-6. XU Peng,HU Guoyan,QIU Pingying,et al.Analysis of CYP2C19 gene polymorphism and metabolic phenotype in schizophrenic patients of Han nationalityin South China[J].Shenzhen Journal of Integrated Traditional Chinese and Western Medicine,2017,27(12):4-6.
[9] MAGGO S D,SAVAGE R L,KENNEDY M A.Impact of new genomic technologies onunderstanding adverse drug reactions[J].Clinical Pharmacokinetics,2016,55(4):419-436.
[10] 周健,李虓,王刚,等.中国健康人群与精神分裂症患者CYP2D6(C100T)遗传多态性的相关研究[J].现代检验医学杂志,2008,23(5):39-41.ZHOU Jian,LI Xiao,WANG Gang,et al.CYP2D6 genetic polymorphisms in Chinese healthy and schizophrenia populations[J].J Mod Lab Med,2008,23(5):39-41.
[11] 翟晓艳,崔炜,张亚楠,等.国人CYP2D6*10基因多态性研究[J].河北医科大学学报,2010,31(2):128-131.ZHAI Xiaoyan,CUI Wei,ZHANG Yanan,et al.Ge-ne polymorphisms ofCYP2D6*10 in Chinese population[J].J Hebei Med Univ,2010,31(2):128-131.
[12] 曾雷,元静,卫芋君,等.CYP2D6基因多态性与分裂症易感性及利培酮治疗反应的研究进展[J].国际精神病学杂志,2018,45(1):18-21.ZENG Lei,YUAN Jing,WEI Yujun,et al.The research progress on polymorphism of CYP2D6 gene and susceptibility to schizophrenia and risperidone treatment[J].Journal of International Psychiatry,2018,45(1):18-21.
[13] 刘芳,苗青,焦伟伟,等.NAT2和CYP2E1基因多态性及其代谢表型在中国汉族儿童中的分布[J].中国当代儿科杂志,2012,14(5):353-358.LIU Fang,MIAO Qing,JIAO Weiwei,et al.Genotype and phenotype polymorphisms of NAT2 and CYP2E1 in the Han Chinese pediatric population[J].Chin J Contemp Pediatr,2012,14(5):353-358.
[14] FLEEMAN N,MCLEOD C,BAGUST A,et al.The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics:a systematic review and economic evaluation[J].Health Technol Assess,2010,14(3):1-157,iii.
[15] MULLER D J,ZAI C C,SICARD M,et al.Systematic analysis of dopamine receptor genes(DRD1-DRD5)in antipsychotic induced weight gain[J].Pharmacogenomics J,2012,12(2):156-164.
[16] 陈柯霖,张国军,吕虹,等.CYP1A2基因C163A多态性与精神分裂症易感性的相关研究[J].中国医药生物技术,2015,10(2):182-183.CHEN Kelin,ZHANG Guojun,L(¨overU)Hong,et al.Co-rrelation study between polymophism of CYPIA2 gene C163A and susceptibility to schizophrenia[J].Chin Med Biotechnol,2015,10(2):182-183.
[17] SARGINSON J E,LAZZERONI L C,RYAN H S,et al.FKBP5 polymorphisms and antidepressant response in geriatric depression[J].American Journal of MedicalGenetics B:Neuropsychiatric Genetics,2010,153B(2):554-560.
[18] DI GIORGIO A,SMITH RM,FAZIO L,et al.DR-D2/CHRNA5 interaction on prefrontal biology and physiology during working memory[J].PLoS One,2014,9(5):e95997.
[19] Schizophrenia Working Group of the Psychiatric Genomics Consortum.Biological insights from 108 schizophrenia-associated genetic loci[J].Nature,2014,511(7510):421-427.
[20] 王丽萍,曾俊芬,宋金春.5-HTR2A 102T>C基因多态性与抗精神病药物疗效的Meta-分析[J].药物评价研究,2018,41(4):656-663.WANG Liping,ZENG Junfen,SONG Jinchun.Correlation of 5-HTR2A gene with102T>C polymorphism and clinical efficacy of antipsychotics based on meta-analysis[J].Drug Evaluation Research,2018,41(4):656-663.
[21] FAKRA E,AZORIN J M.Clozapine for the treatment of schizophrenia[J].Expert Opin Pharmacother,2012,13(13):1923-1935.
相似文献/References:
[1]苏显都a,范长玲a,于 莉a,等.琼西地区精神分裂症患者血浆MiR-137,MiR-181b及MiR-132表达及其相关性研究[J].现代检验医学杂志,2016,31(04):30.[doi:10.3969/j.issn.16717-414.2016.04.007]
SU Xian-dua,FAN Chang-linga,YU Lia,et al.Expression of Plasma MiR-137,MiR-181b and MiR-132
of Schizophrenia Patients in Qiongxi Area and Its Correlation Study[J].Journal of Modern Laboratory Medicine,2016,31(03):30.[doi:10.3969/j.issn.16717-414.2016.04.007]
[2]苏显都a,范长玲a,于 莉a,等.血浆及单核细胞中microRNA表达水平与精神分裂症患者的相关性研究[J].现代检验医学杂志,2017,32(02):45.[doi:10.3969/j.issn.1671-7414.2017.02.012]
SU Xian-dua,FAN Chang-linga,YU Lia,et al.Association of Epression with the Level of MicroRNA
in Plasma and Mononuclear Cells in Patients with Schizophrenia[J].Journal of Modern Laboratory Medicine,2017,32(03):45.[doi:10.3969/j.issn.1671-7414.2017.02.012]
[3]谭梅娟,李 靖.精神分裂症患者梅毒感染的流行病学调查[J].现代检验医学杂志,2018,33(04):125.[doi:10.3969/j.issn.1671-7414.2018.04.034]
TAN Mei-juan,LI Jing.Study on Syphilis Infection among Inpatients with Schizophrenia[J].Journal of Modern Laboratory Medicine,2018,33(03):125.[doi:10.3969/j.issn.1671-7414.2018.04.034]
[4]段侠霞a,张 燕b,贺瑞峰a,等.儿童青少年精神分裂症与血清甲状腺激素水平的相关性分析[J].现代检验医学杂志,2018,33(06):80.[doi:10.3969/j.issn.1671-7414.2018.06.021]
DUAN Xia-xiaa,ZHANG Yanb,HE Rui-fenga,et al.Correlation Analysis on Children and Adolescents with Schizophrenia and Serum Thyroid Hormones[J].Journal of Modern Laboratory Medicine,2018,33(03):80.[doi:10.3969/j.issn.1671-7414.2018.06.021]